On March 18th, the "China Pharmaceutical Enterprise Research and Development Index", a research and development index targeting pharmaceutical enterprises, was officially released in Beijing. According to the White Paper on the R&D Index of Chinese Pharmaceutical Enterprises, the overall average and median values of the "R&D Index of Chinese Pharmaceutical Enterprises" for non device categories showed a slow upward trend from 2013 to 2021. The average value increased from 60.673 in 2013 to 61.146 in 2021.

According to the white paper, Hengrui Pharmaceutical, Huahai Pharmaceutical, Humanwell Pharmaceutical, Baiji Shenzhou, Haizheng Pharmaceutical, Tianshili, Hansen Pharmaceutical, Yiling Pharmaceutical, etc. ranked first in the research and development index of non device Chinese pharmaceutical enterprises in 2021.

Hengrui Pharmaceutical

Hengrui Pharmaceutical is one of the largest R&D pharmaceutical companies in China, committed to innovative development in the fields of anti-tumor drugs, anesthetics, contrast agents, autoimmune diseases, chronic diseases, and other diseases. According to Hengrui Pharmaceutical's financial report, from 2018 to the first three quarters of 2022, Hengrui Pharmaceutical's R&D expenses were 2.67 billion yuan, 3.896 billion yuan, 4.989 billion yuan, 5.943 billion yuan, and 3.498 billion yuan, respectively. The proportion of R&D expenses in revenue increased from 15.33% to 21.93%.